RESUMEN
PURPOSE: The purpose of this review is to examine the current evidence on the potential role of Mediterranean diet (MD) in the prevention and management of endocrine disorders and to highlight the importance of interdisciplinary collaboration between endocrinologists and nutritionists. METHODS: A literature search was conducted using PubMed and Google Scholar databases to identify relevant studies published in English. Studies were selected based on their relevance to the role of MD in the prevention and management of endocrine disorders. The search terms included "Mediterranean diet," "endocrine disorders," "thyroid disorders," "gonadal disorders," and "neuroendocrine tumors". RESULTS: The studies reviewed suggest that MD may have a beneficial effect in the prevention and management of various endocrine disorders, including thyroid disorders, gonadal disorders, and neuroendocrine tumors. MD has been associated with decreased risk of nodular thyroid disease and thyroid cancer, improved male and female reproductive health, and a potential role in the management of neuroendocrine tumors. MD's anti-inflammatory and antioxidant properties, as well as its high levels of phytochemicals, may play a role in its beneficial effects. CONCLUSION: Interdisciplinary collaboration between endocrinologists and nutritionists is essential for the optimal management of endocrine disorders, including the potential role of MD in their prevention and management. While further research is needed, the current evidence suggests that MD may have a protective effect against endocrine disorders, and its incorporation into dietary recommendations may be beneficial.
Asunto(s)
Dieta Mediterránea , Enfermedades del Sistema Endocrino , Tumores Neuroendocrinos , Nutricionistas , Humanos , Masculino , Femenino , Endocrinólogos , Enfermedades del Sistema Endocrino/prevención & controlRESUMEN
Increasing prevalence of lifestyle diseases raised global awareness about health consequences of human exposure to endocrine disruptors (EDs): synthetic chemicals that mimic natural hormones and affect the biochemical and endocrine balance. As home environment is one of the main sources of the exposure to xenobiotics - especially for pregnant women, infants and young children - health organizations emphasize the need of implementing lifestyle changes to protect human health and child development. The aim of this study was to evaluate the effectiveness of introducing changes in daily life in lowering the exposure to selected EDs in the indoor home environment. Twenty-six healthy volunteers from 9 households from Gdansk (Poland) were enrolled and their home- and lifestyle-related exposure to EDs was analyzed using a designed questionnaire and algorithm. Urine and dust samples were collected before and after introducing the recommended lifestyle changes. The concentrations of selected EDs in the samples were determined using liquid chromatography-electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS). This pilot study confirmed the ubiquity of harmful chemicals in the home environment and the importance of exposure related to a daily routine. Importantly, it proved that lifestyle modifications implemented by participants led to a significant decrease in both, their home-related exposure to EDs, as well as in urine concentrations of these chemicals. It also demonstrated a need for determining EDs exposure and introducing lifestyle changes as a useful tool for prevention of lifestyle-related diseases.
Asunto(s)
Actividades Cotidianas , Disruptores Endocrinos/efectos adversos , Ambiente , Exposición a Riesgos Ambientales/efectos adversos , Vivienda , Estilo de Vida , Algoritmos , Niño , Preescolar , Polvo/análisis , Disruptores Endocrinos/orina , Enfermedades del Sistema Endocrino/prevención & control , Composición Familiar , Femenino , Voluntarios Sanos , Humanos , Lactante , Masculino , Proyectos Piloto , Polonia , Encuestas y CuestionariosRESUMEN
The 2019 Coronavirus disease (COVID-19) pandemic has disrupted the social, economical and medical system worldwide. Although it is strictly an infectious disease, its intricate bidirectional relationship with various non-communicable metabolic diseases and endocrinological factors has been observed. While diabetes, hypertension, obesity have been found to be independent risk factors for COVID-19 disease severity and mortality, more inclination towards sedentary lifestyle, psychosocial stress at this critical time may be the harbingers of metabolic syndrome. Thus, endocrinologists have a great opportunity to play their role to combat this pandemic. This paper examines how various endocrinological disorders influence the dynamics of COVID-19 and vice versa. Moreover, it also intends to review the clinical guidelines to be adopted in practice of endocrinology in this trying time.
Asunto(s)
Infecciones por Coronavirus , Enfermedades del Sistema Endocrino/prevención & control , Endocrinología/tendencias , Pandemias , Neumonía Viral , COVID-19 , Infecciones por Coronavirus/complicaciones , Promoción de la Salud , Humanos , Estilo de Vida , Neumonía Viral/complicaciones , Factores de RiesgoRESUMEN
With the ageing of the global population, interest is growing in the 'geroscience hypothesis', which posits that manipulation of fundamental ageing mechanisms will delay (in parallel) the appearance or severity of multiple chronic, non-communicable diseases, as these diseases share the same underlying risk factor - namely, ageing. In this context, cellular senescence has received considerable attention as a potential target in preventing or treating multiple age-related diseases and increasing healthspan. Here we review mechanisms of cellular senescence and approaches to target this pathway therapeutically using 'senolytic' drugs that kill senescent cells or inhibitors of the senescence-associated secretory phenotype (SASP). Furthermore, we highlight the evidence that cellular senescence has a causative role in multiple diseases associated with ageing. Finally, we focus on the role of cellular senescence in a number of endocrine diseases, including osteoporosis, metabolic syndrome and type 2 diabetes mellitus, as well as other endocrine conditions. Although much remains to be done, considerable preclinical evidence is now leading to the initiation of proof-of-concept clinical trials using senolytics for several endocrine and non-endocrine diseases.
Asunto(s)
Envejecimiento/fisiología , Senescencia Celular , Enfermedades del Sistema Endocrino/prevención & control , Enfermedades del Sistema Endocrino/fisiopatología , Animales , Enfermedades del Sistema Endocrino/etiología , Humanos , Factores de RiesgoRESUMEN
Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) are increasingly recognized, characterized by prolonged survival even with metastatic disease. Their medical treatment is complex involving various specialties, necessitating awareness of treatment-related adverse effects (AEs). As GEP-NENs express somatostatin receptors (SSTRs), long-acting somatostatin analogs (SSAs) that are used for secretory syndrome and tumor control may lead to altered glucose metabolism. Everolimus and sunitinib are molecular targeted agents that affect glucose and lipid metabolism and may induce hypothyroidism or hypocalcemia, respectively. Chemotherapeutic drugs can affect the reproductive system and water homeostasis, whereas immunotherapeutic agents can cause hypophysitis and thyroiditis or other immune-mediated disorders. Treatment with radiopeptides may temporarily lead to radiation-induced hormone disturbances. As drugs targeting GEP-NENs are increasingly introduced, recognition and management of endocrine-related AEs may improve compliance and the quality of life of these patients.
Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Enfermedades del Sistema Endocrino/inducido químicamente , Neoplasias Intestinales/tratamiento farmacológico , Tumores Neuroendocrinos/tratamiento farmacológico , Neoplasias Pancreáticas/tratamiento farmacológico , Neoplasias Gástricas/tratamiento farmacológico , Antineoplásicos Inmunológicos/efectos adversos , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Carcinoma Neuroendocrino/tratamiento farmacológico , Ingestión de Líquidos/efectos de los fármacos , Enfermedades del Sistema Endocrino/epidemiología , Enfermedades del Sistema Endocrino/prevención & control , Enfermedades del Sistema Endocrino/terapia , Neoplasias Gastrointestinales/tratamiento farmacológico , Genitales/efectos de los fármacos , Genitales/fisiología , Humanos , Enfermedades del Sistema Inmune/inducido químicamente , Enfermedades del Sistema Inmune/epidemiología , Enfermedades del Sistema Inmune/terapia , Desequilibrio Hidroelectrolítico/inducido químicamente , Desequilibrio Hidroelectrolítico/epidemiología , Desequilibrio Hidroelectrolítico/prevención & controlRESUMEN
The use of opioids is becoming a global epidemic, leading to a rise in the occurrence and recognition of the effects of opioid drugs on the endocrine system. Nonetheless, opioid-induced endocrinopathies still remain underdiagnosed, mainly because of symptom under-reporting by patients and poor clinician awareness. Hypogonadism is the most well recognised consequence of opioid use, but the inhibitory effects of opioid drugs on the hypothalamo-pituitary-adrenal axis and their negative effects on bone health also require attention. Hyperprolactinaemia might be detected in opioid users, but clinically relevant thyroid dysfunction has not been identified. The effects of opioids on other hormones have not been clearly defined. Assessment of gonadal and adrenal function (particularly if high index of clinical suspicion of hypogonadism or hypoadrenalism) and evaluation of bone health are advised in people that use opiods. Discontinuation or reduction of opioid dose and appropriate hormone replacement are the management approaches that should be considered for hypogonadism and hypoadrenalism. Further research is needed to facilitate the development of evidence-based guidelines on the diagnosis and optimal management of opioid-induced endocrinopathies.
Asunto(s)
Analgésicos Opioides/efectos adversos , Enfermedades del Sistema Endocrino/inducido químicamente , Enfermedades del Sistema Endocrino/prevención & control , Terapia de Reemplazo de Hormonas , Humanos , Hipogonadismo/inducido químicamente , Hipogonadismo/prevención & control , Sistema Hipotálamo-Hipofisario/efectos de los fármacos , Sistema Hipotálamo-Hipofisario/metabolismo , Trastornos Relacionados con Opioides/complicaciones , Sistema Hipófiso-Suprarrenal/efectos de los fármacos , Sistema Hipófiso-Suprarrenal/metabolismoRESUMEN
Introduction of MRI techniques for identifying and monitoring tissue iron overload and the current understanding of iron homeostasis in transfusion-dependent (TDT) and non-transfusion-dependent thalassemia have allowed for a more robust administration of iron chelation therapies. The development of safe and efficient oral iron chelators and the insights gained from large-scale prospective studies using these agents have improved iron overload management. A significant reduction in iron toxicity-induced morbidity and mortality and improvements in quality of life were observed in TDT. The appropriate management of tissue-specific iron loading in TDT has been portrayed using evidence-based data obtained from investigational studies.
Asunto(s)
Quelantes del Hierro/uso terapéutico , Sobrecarga de Hierro/tratamiento farmacológico , Sobrecarga de Hierro/etiología , Talasemia/complicaciones , Biomarcadores , Transfusión Sanguínea , Terapia por Quelación , Enfermedades del Sistema Endocrino/tratamiento farmacológico , Enfermedades del Sistema Endocrino/etiología , Enfermedades del Sistema Endocrino/metabolismo , Enfermedades del Sistema Endocrino/prevención & control , Humanos , Hierro/metabolismo , Sobrecarga de Hierro/diagnóstico , Sobrecarga de Hierro/metabolismo , Hígado/diagnóstico por imagen , Hígado/metabolismo , Hígado/patología , Imagen por Resonancia Magnética , Talasemia/metabolismo , Talasemia/terapiaRESUMEN
Millions of people consume betel nut for increased capacity to work and for stress reduction. The nut contains arecoline, which has multiple side effects on endocrine functions. Objective of the work is to investigate pineal-testicular responses to noise and after arecoline treatment in noise in rats. Noise exposure (100 dB, 6 h daily, 10 days) caused pineal stimulation ultrastructurally and at indoleamines level. Leydig cell dysfunction with fall of testosterone level and suppression of sex accessories were noticed. In contrast, pineal activity was inhibited and reproductive functions were stimulated after arecoline administration, confirmed from reversed changes to those of noise. Arecoline treatment in noise exposure showed same results as in noise both in pineal and in reproductive functions. It is concluded that noise causes testicular dysfunction probably by gonadotropin suppression induced by pineal melatonin in noise. Furthermore, arecoline cannot prevent it in noise in rats.
Asunto(s)
Arecolina/uso terapéutico , Enfermedades del Sistema Endocrino/prevención & control , Ruido/efectos adversos , Glándula Pineal/efectos de los fármacos , Sustancias Protectoras/uso terapéutico , Enfermedades Testiculares/prevención & control , Testículo/efectos de los fármacos , Animales , Arecolina/administración & dosificación , Biomarcadores/sangre , Biomarcadores/metabolismo , Núcleo Celular/efectos de los fármacos , Núcleo Celular/efectos de la radiación , Núcleo Celular/ultraestructura , Agonistas Colinérgicos/uso terapéutico , Enfermedades del Sistema Endocrino/etiología , Enfermedades del Sistema Endocrino/patología , Enfermedades del Sistema Endocrino/fisiopatología , Inyecciones Intraperitoneales , Células Intersticiales del Testículo/efectos de los fármacos , Células Intersticiales del Testículo/metabolismo , Células Intersticiales del Testículo/efectos de la radiación , Células Intersticiales del Testículo/ultraestructura , Masculino , Microscopía Electrónica de Transmisión , Mitocondrias/efectos de los fármacos , Mitocondrias/efectos de la radiación , Mitocondrias/ultraestructura , Ácido N-Acetilneuramínico/metabolismo , Glándula Pineal/fisiopatología , Glándula Pineal/efectos de la radiación , Glándula Pineal/ultraestructura , Sustancias Protectoras/administración & dosificación , Ratas Wistar , Vesículas Seminales/efectos de los fármacos , Vesículas Seminales/metabolismo , Vesículas Seminales/fisiopatología , Vesículas Seminales/efectos de la radiación , Enfermedades Testiculares/etiología , Enfermedades Testiculares/patología , Enfermedades Testiculares/fisiopatología , Testículo/fisiopatología , Testículo/efectos de la radiación , Testículo/ultraestructura , Testosterona/metabolismoAsunto(s)
Investigación Biomédica/métodos , Endocrinología/métodos , Medicina Reproductiva/métodos , Investigación Biomédica/educación , Investigación Biomédica/tendencias , Sistema Endocrino/fisiología , Sistema Endocrino/fisiopatología , Enfermedades del Sistema Endocrino/fisiopatología , Enfermedades del Sistema Endocrino/prevención & control , Enfermedades del Sistema Endocrino/terapia , Endocrinología/educación , Endocrinología/tendencias , Femenino , Enfermedades de los Genitales Femeninos/fisiopatología , Enfermedades de los Genitales Femeninos/prevención & control , Enfermedades de los Genitales Femeninos/terapia , Genitales Femeninos/fisiología , Genitales Femeninos/fisiopatología , Humanos , Liderazgo , Medicina Reproductiva/educación , Medicina Reproductiva/tendencias , Investigación Biomédica Traslacional/educación , Investigación Biomédica Traslacional/métodos , Investigación Biomédica Traslacional/tendencias , Recursos HumanosRESUMEN
CONTEXT: Endocrine-metabolic disease (EMD) risk following spinal cord injury (SCI) is associated with significant multi-morbidity (i.e. fracture, diabetes, heart disease), mortality, and economic burden. It is unclear to what extent rehabilitation interventions can modify EMD risk and improve health status in community-dwelling adults with chronic SCI. OBJECTIVES: To characterize rehabilitation interventions and summarize evidence on their efficacy/effectiveness to modify precursors to EMD risk in community-dwelling adults with chronic SCI. METHODS: Systematic searches of MEDLINE PubMed, EMBASE Ovid, CINAHL, CDSR, and PsychInfo were completed. All randomized, quasi-experimental, and prospective controlled trials comparing rehabilitation/therapeutic interventions with control/placebo interventions in adults with chronic SCI were eligible. Two authors independently selected studies and abstracted data. Mean differences of change from baseline were reported for EMD risk outcomes. The GRADE approach was used to rate the quality of evidence. RESULTS: Of 489 articles identified, 16 articles (11 studies; n=396) were eligible for inclusion. No studies assessed the effects of rehabilitation interventions on incident fragility fractures, heart disease, and/or diabetes. Individual studies reported that exercise and/or nutrition interventions could improve anthropometric indices, body composition/adiposity, and biomarkers. However, there were also reports of non-statistically significant between-group differences. CONCLUSIONS: There was very low-quality evidence that rehabilitation interventions can improve precursors to EMD risk in community-dwelling adults with chronic SCI. The small number of studies, imprecise estimates, and inconsistency across studies limited our ability to make conclusions. A high-quality longitudinal intervention trial is needed to inform community-based rehabilitation strategies for EMD risk after chronic SCI.
Asunto(s)
Enfermedades del Sistema Endocrino/prevención & control , Terapia por Ejercicio/métodos , Enfermedades Metabólicas/prevención & control , Rehabilitación Neurológica/métodos , Terapia Nutricional/métodos , Traumatismos de la Médula Espinal/rehabilitación , Enfermedades del Sistema Endocrino/etiología , Terapia por Ejercicio/efectos adversos , Humanos , Vida Independiente , Enfermedades Metabólicas/etiología , Terapia Nutricional/efectos adversos , Traumatismos de la Médula Espinal/complicacionesRESUMEN
Two types of immune checkpoint inhibitors, both antibodies that target cytotoxic T-lymphocyte antigen-4 and those that target programmed cell death-protein 1, have been approved for use in melanoma, non-small-cell lung cancer, and renal cell carcinoma as first-line or second-line therapy. Their adverse events are primarily regarded as immune-related adverse events. We felt it was important to pinpoint and discuss certain preconceptions or misconceptions regarding thyroid dysfunction, hypophysitis, and diabetes induced by immune checkpoint inhibitors. We have identified areas of uncertainty and unmet requirements, including essential interaction between endocrinologists and oncologists. Five issues have been identified for discussion: (1) diagnosis of endocrine toxicity, (2) assessment of toxicity severity, (3) treatment of toxicity, (4) withdrawal or continuation of immunotherapy, (5) preventive action.
Asunto(s)
Antineoplásicos Inmunológicos/efectos adversos , Sistema Endocrino/efectos de los fármacos , Inmunomodulación/efectos de los fármacos , Anticuerpos Monoclonales/efectos adversos , Antígeno B7-H1/antagonistas & inhibidores , Biomarcadores de Tumor , Antígeno CTLA-4/antagonistas & inhibidores , Toma de Decisiones Clínicas , Manejo de la Enfermedad , Enfermedades del Sistema Endocrino/diagnóstico , Enfermedades del Sistema Endocrino/etiología , Enfermedades del Sistema Endocrino/prevención & control , Enfermedades del Sistema Endocrino/terapia , Endocrinólogos , Humanos , Inmunoterapia , Comunicación Interdisciplinaria , Oncólogos , Receptor de Muerte Celular Programada 1/antagonistas & inhibidores , Índice de Severidad de la EnfermedadRESUMEN
Gamma Knife radiosurgery (GK) is an effective treatment for hypothalamic hamartoma. No precise data are available on the risk of endocrine side effects of this treatment. In this study, 34 patients with hypothalamic hamartoma (HH) were followed prospectively at the Department of Endocrinology, La Timone Hospital, Marseille, France, for a mean follow-up of >2 years (mean ± standard deviation [SD] 3.6 ± 2 years). Initial pre- and post-GK radiosurgery evaluations were performed, including weight, body mass index (BMI), and a complete endocrinological workup. At diagnosis, eight patients presented with central precocious puberty at a mean age of 5.4 ± 2.4 years. At the time of GK (mean age 18.2 ± 11.1 years), two patients previously treated with surgery presented with luteinizing hormone/follicle-stimulating hormone (LH/FSH) deficiency. After GK, only one patient presented with a new thyrotropin-stimulating hormone (TSH) deficiency, 2 years after the procedure. The other pituitary axes remained normal in all but two patients (who had LH/FSH deficiency prior to GK). There was no significant difference between pre- and post-GK mean BMI (26.9 vs. 25.1 kg/m2 , p = 0.59). To conclude, in this group of 34 patients, GK did not induce major endocrinologic side effects reported with all the other surgical techniques in the literature. It is, thus, a safe and effective procedure in the treatment of hypothalamic hamartoma.
Asunto(s)
Enfermedades del Sistema Endocrino/etiología , Enfermedades del Sistema Endocrino/prevención & control , Hamartoma/cirugía , Enfermedades Hipotalámicas/cirugía , Complicaciones Posoperatorias/etiología , Complicaciones Posoperatorias/prevención & control , Radiocirugia , Adolescente , Adulto , Niño , Preescolar , Femenino , Estudios de Seguimiento , Hormona Liberadora de Gonadotropina/deficiencia , Hamartoma/complicaciones , Humanos , Enfermedades Hipotalámicas/complicaciones , Hipotiroidismo/etiología , Hipotiroidismo/cirugía , Masculino , Persona de Mediana Edad , Pubertad Precoz/etiología , Pubertad Precoz/cirugía , Factores de Riesgo , Adulto JovenRESUMEN
PURPOSE: Although physical activity is an established risk factor for chronic disease prevention, the specific mechanisms underlying these relationships are poorly understood. We examined the associations between total activity counts and moderate-vigorous physical activity (MVPA) measured by accelerometer, and physical activity energy expenditure measured by doubly labeled water, with plasma levels of proinsulin, insulin, c-peptide, insulin growth factor binding protein-3, insulin growth factor-1, adiponectin, leptin, and leptin-sR. METHODS: We conducted a cross-sectional analysis of 526 healthy US women in the Women's Lifestyle Validation Study, 2010 to 2012. We performed multiple linear regression models adjusting for potential lifestyle and health-related confounders to assess the associations between physical activity, measured in quartiles (Q) and biomarkers. RESULTS: Participants in Q4 versus Q1 of total activity counts had lower proinsulin (-20%), c-peptide (-7%), insulin (-31%), and leptin (-46%) levels, and higher adiponectin (55%), leptin-sR (25%), and insulin growth factor-1 (9.6%) levels (all P trend ≤ 0.05). Participants in Q4 versus Q1 of MVPA had lower proinsulin (-26%), c-peptide (-7%), insulin (-32%), and leptin (-40%) levels, and higher adiponectin (31%) and leptin-sR (22%) levels (all P trend ≤ 0.05). Further adjustment for body mass index (BMI) attenuated these associations, but the associations with adipokines remained significant. Those in Q4 versus Q1 of physical activity energy expenditure had lower leptin (-21%) and higher leptin-sR (10%) levels (all P trend ≤ 0.05), after additional adjustment for BMI. In the sensitivity analysis, the associations were similar but attenuated when physical activity was measured using the subjective physical activity questionnaire. CONCLUSIONS: Our data suggest that greater physical activity is modestly associated with favorable levels of cardiometabolic and endocrine biomarkers, where the strongest associations were found with accelerometer-measured physical activity. These associations may be only partially mediated through BMI, further supporting the role of physical activity in the reduction of cardiometabolic and endocrine disease risk, independent of adiposity.
Asunto(s)
Biomarcadores/sangre , Enfermedades Cardiovasculares/prevención & control , Enfermedades del Sistema Endocrino/prevención & control , Ejercicio Físico/fisiología , Acelerometría , Adiponectina/sangre , Anciano , Índice de Masa Corporal , Péptido C/sangre , Estudios Transversales , Metabolismo Energético/fisiología , Femenino , Humanos , Insulina/sangre , Proteína 3 de Unión a Factor de Crecimiento Similar a la Insulina/sangre , Factor I del Crecimiento Similar a la Insulina/metabolismo , Leptina/sangre , Persona de Mediana Edad , Proinsulina/sangre , Factores de RiesgoRESUMEN
After immune checkpoint inhibitor therapy was approved for renal cell carcinoma last year, this new immune therapy has spread to urology. Further approvals (atezolizumab, nivolumab, pembrolizumab) are expected in 2017 for metastatic urothelial carcinoma that has progressed following treatment with platinum-based chemotherapy. With expanding use of immune checkpoint inhibitors, experience in diagnosing and managing immune-mediated adverse events increases. Although of low incidence, grade 3/4 toxicities play a central role. Organs most common for immune-mediated adverse events are skin, liver (hepatitis), kidneys (nephritis), gastrointestinal tract (diarrhea and colitis), lungs (pneumonitis), and endocrine organs (hyper-, hypothyroidism and hypophysitis). Diagnostic workup includes routine laboratory tests (including liver function tests) and may be supplemented with hormone values. In cases of pneumonitis or hypophysitis, imaging (high-resolution CT, MRI) can confirm diagnoses. Immune-mediated toxicities are treated with therapy interruption and administration of corticosteroids (and in individual cases additional immunosuppression). Dose modification is not intended!
Asunto(s)
Antineoplásicos/efectos adversos , Enfermedad Hepática Inducida por Sustancias y Drogas/etiología , Enfermedades Gastrointestinales/inducido químicamente , Inmunosupresores/administración & dosificación , Enfermedades Renales/inducido químicamente , Neumonía/inducido químicamente , Enfermedades de la Piel/inducido químicamente , Anticuerpos Monoclonales , Proteínas de Ciclo Celular/antagonistas & inhibidores , Enfermedad Hepática Inducida por Sustancias y Drogas/prevención & control , Relación Dosis-Respuesta a Droga , Enfermedades del Sistema Endocrino/inducido químicamente , Enfermedades del Sistema Endocrino/prevención & control , Medicina Basada en la Evidencia , Enfermedades Gastrointestinales/prevención & control , Humanos , Inmunoterapia/efectos adversos , Enfermedades Renales/prevención & control , Neumonía/prevención & control , Enfermedades de la Piel/prevención & control , Resultado del Tratamiento , Neoplasias Urológicas/complicaciones , Neoplasias Urológicas/tratamiento farmacológicoRESUMEN
BACKGROUND: Childhood cancer survivors are at a higher risk of developing health conditions such as osteoporosis, and cardiovascular disease than their peers. Health-promoting behaviour, such as consuming a healthy diet, could lessen the impact of these chronic issues, yet the prevalence rate of health-protecting behaviour amongst survivors of childhood cancer is similar to that of the general population. Targeted nutritional interventions may prevent or reduce the incidence of these chronic diseases. OBJECTIVES: The primary aim of this review was to assess the efficacy of a range of nutritional interventions designed to improve the nutritional intake of childhood cancer survivors, as compared to a control group of childhood cancer survivors who did not receive the intervention. Secondary objectives were to assess metabolic and cardiovascular risk factors, measures of weight and body fat distribution, behavioural change, changes in knowledge regarding disease risk and nutritional intake, participants' views of the intervention, measures of health status and quality of life, measures of harm associated with the process or outcomes of the intervention, and cost-effectiveness of the intervention SEARCH METHODS: We searched the electronic databases of the Cochrane Central Register of Controlled Trials (CENTRAL; 2013, Issue 3), MEDLINE/PubMed (from 1945 to April 2013), and Embase/Ovid (from 1980 to April 2013). We ran the search again in August 2015; we have not yet fully assessed these results, but we have identified one ongoing trial. We conducted additional searching of ongoing trial registers - the International Standard Randomised Controlled Trial Number register and the National Institutes of Health register (both screened in the first half of 2013) - reference lists of relevant articles and reviews, and conference proceedings of the International Society for Paediatric Oncology and the International Conference on Long-Term Complications of Treatment of Children and Adolescents for Cancer (both 2008 to 2012). SELECTION CRITERIA: We included all randomised controlled trials (RCTs) that compared the effects of a nutritional intervention with a control group which did not receive the intervention in this review. Participants were childhood cancer survivors of any age, diagnosed with any type of cancer when less than 18 years of age. Participating childhood cancer survivors had completed their treatment with curative intent prior to the intervention. DATA COLLECTION AND ANALYSIS: Two review authors independently selected and extracted data from each identified study, using a standardised form. We assessed the validity of each identified study using the criteria outlined in the Cochrane Handbook for Systematic Reviews of Interventions. We used the GRADE criteria to assess the quality of each trial. MAIN RESULTS: Three RCTs were eligible for review. A total of 616 participants were included in the analysis. One study included participants who had been treated for acute lymphoblastic leukaemia (ALL) (275 participants). Two studies included participants who had all forms of paediatric malignancies (266 and 75 participants). All participants were less than 21 years of age at study entry. The follow-up ranged from one month to 36 months from the initial assessment. All intended outcomes were not evaluated by each included study. All studies looked at different interventions, and so we were unable to pool results. We could not rule out the presence of bias in any of the studies.There was no clear evidence of a difference in calcium intake at one month between those who received the single, half-day, group-based education that focused on bone health, and those who received standard care (mean difference (MD) 111.60, 95% confidence interval (CI) -258.97 to 482.17; P = 0.56, low quality evidence). A regression analysis, adjusting for baseline calcium intake and changes in knowledge and self-efficacy, showed a significantly greater calcium intake for the intervention as compared with the control group at the one-month follow-up (beta coefficient 4.92, 95% CI 0.33 to 9.52; P = 0.04). There was statistically significant higher, self-reported milk consumption (MD 0.43, 95% CI 0.07 to 0.79; P = 0.02, low quality evidence), number of days on calcium supplementation (MD 11.42, 95% CI 7.11 to 15.73; P < 0.00001, low quality evidence), and use of any calcium supplementation (risk ratio (RR) 3.35, 95% CI 1.86 to 6.04; P < 0.0001, low quality evidence), with those who received this single, face-to-face, group-based, health behaviour session.There was no clear evidence of a difference in bone density Z-scores measured with a dual-energy X-ray absorptiometry (DEXA) scan at 36 months follow-up (MD -0.05, 95% CI -0.26 to 0.16; P = 0.64, moderate quality evidence) between those who received calcium and vitamin D supplementation combined with nutrition education and those who received nutrition education alone. There was also no clear evidence of a difference in bone mineral density between the intervention and the control group at the 12-month (median difference -0.17, P = 0.99) and 24-month follow-up (median difference -0.04, P = 0.54).A single multi-component health behaviour change intervention, focusing on general healthy eating principles, with two telephone follow-ups brought about a 0.17 lower score on the four-point Likert scale of self-reported junk food intake compared with the control group (MD -0.17, 95% CI -0.33 to -0.01; P = 0.04, low quality evidence); this result was statistically significant. There was no clear evidence of a difference between the groups in the self-reported use of nutrition as a health protective behaviour (MD -0.05, 95% CI -0.24 to 0.14; P = 0.60, low quality evidence). AUTHORS' CONCLUSIONS: Due to a paucity of studies, and the heterogeneity of the studies included in this review, we are unable to draw conclusions regarding the effectiveness of nutritional interventions for use with childhood cancer survivors. Although there is low quality evidence for the improvement in health behaviours using health behaviour change interventions, there remains no evidence as to whether this translates into an improvement in dietary intake. There was also no evidence that the studies reduced the risk of cardiovascular and metabolic disorders in childhood cancer survivors, although no evidence of effect is not the same as evidence of no effect. This review highlights the need for further well designed trials to be implemented in this population.
Asunto(s)
Calcio de la Dieta/administración & dosificación , Conductas Relacionadas con la Salud , Neoplasias , Terapia Nutricional/métodos , Sobrevivientes , Vitamina D/administración & dosificación , Vitaminas/administración & dosificación , Adolescente , Animales , Densidad Ósea , Enfermedades Cardiovasculares/prevención & control , Niño , Enfermedades del Sistema Endocrino/prevención & control , Comida Rápida , Humanos , Análisis de Intención de Tratar , Síndrome Metabólico/prevención & control , Leche , Neoplasias/terapia , Osteoporosis/prevención & control , Leucemia-Linfoma Linfoblástico de Células Precursoras/terapia , Ensayos Clínicos Controlados Aleatorios como Asunto , Adulto JovenRESUMEN
PURPOSE OF REVIEW: Skeletal muscle is gaining increased attention as an endocrine organ. Recently, novel myokines and new effects of already established myokines have been identified. The objective of this review is to give an update on the recent advances in the field. RECENT FINDINGS: Several hundred putative myokines have been described, some of which are induced by contraction and differentially regulated between healthy and metabolically diseased individuals. Interleukin-6 (IL-6) is the prototype myokine, which was identified as a muscle-derived cytokine 15 years ago. Recently, IL-6 has been linked to ß-cell survival and inhibition of cancer-cell growth. Moreover, trans-signaling appears to determine whether IL-6 acts as a proinflammatory or an anti-inflammatory cytokine. Irisin has been shown to be a secreted myokine, which contribute to circulating concentrations dependent on training status. IL-15 has been established as a cytokine mediating cross-talk between skeletal muscle and skin tissue, and decorin has been characterized as a contraction-induced myokine which apparently is differentially regulated between healthy and dysglycemic individuals. SUMMARY: Skeletal muscle is an endocrine organ which, by the release of myokines, may influence metabolism in virtually all organs in the body. This knowledge may potentially open up for the possibility of designing new drugs that mimic the effects of myokine signaling.
Asunto(s)
Sistema Endocrino/metabolismo , Regulación del Desarrollo de la Expresión Génica , Músculo Esquelético/metabolismo , Animales , Citocinas/genética , Citocinas/metabolismo , Sistema Endocrino/crecimiento & desarrollo , Sistema Endocrino/inmunología , Enfermedades del Sistema Endocrino/inmunología , Enfermedades del Sistema Endocrino/metabolismo , Enfermedades del Sistema Endocrino/prevención & control , Ejercicio Físico , Estilo de Vida Saludable , Humanos , Músculo Esquelético/crecimiento & desarrollo , Músculo Esquelético/inmunologíaRESUMEN
Glucosinolates are the major bioactive secondary metabolites found in the Brassicaceae family and studied extensively in biosynthetic and application perspectives. Because of their potential applications in the welfare of plants (protection against plant pathogens) and human life (prevention of cancer and other diseases), these compounds attracted much interest in the scientific community. In this review, we presented updates on glucosinolate derivatives in protection against microbial pathogens and endocrine related diseases in human. Further, the mechanism of action of glucosinolate derivatives and the strategies to improve their efficiency through modern approaches were discussed. Finally, the genetic enrichment of their contents in plant systems has also been discussed.
Asunto(s)
Antiinfecciosos , Enfermedades del Sistema Endocrino/prevención & control , Glucosinolatos/uso terapéutico , Anticarcinógenos , Bacterias/efectos de los fármacos , Biopelículas/efectos de los fármacos , Brassicaceae/química , Glucosinolatos/farmacología , Hormonas , Humanos , Neoplasias/etiología , Neoplasias/prevención & control , Fitoterapia , Enfermedades de las Plantas/prevención & control , Virus/efectos de los fármacosAsunto(s)
Enfermedades del Sistema Endocrino/diagnóstico , Enfermedades Metabólicas/diagnóstico , Niño , Preescolar , Enfermedades del Sistema Endocrino/epidemiología , Enfermedades del Sistema Endocrino/prevención & control , Humanos , Enfermedades Metabólicas/epidemiología , Enfermedades Metabólicas/prevención & control , Microbiota , Prevalencia , Factores de RiesgoRESUMEN
With the completion of the Human Genome Project and advances in genomic sequencing technologies, the use of clinical molecular diagnostics has grown tremendously over the last decade. Next-generation sequencing (NGS) has overcome many of the practical roadblocks that had slowed the adoption of molecular testing for routine clinical diagnosis. In endocrinology, targeted NGS now complements biochemical testing and imaging studies. The goal of this review is to provide clinicians with a guide to the application of NGS to genetic testing for endocrine conditions, by compiling a list of established gene mutations detectable by NGS, and highlighting key phenotypic features of these disorders. As we outline in this review, the clinical utility of NGS-based molecular testing for endocrine disorders is very high. Identifying an exact genetic etiology improves understanding of the disease, provides clear explanation to families about the cause, and guides decisions about screening, prevention and/or treatment. To illustrate this approach, a case of hypophosphatasia with a pathogenic mutation in the ALPL gene detected by NGS is presented.
Asunto(s)
Glándulas Endocrinas/patología , Enfermedades del Sistema Endocrino/genética , Secuenciación de Nucleótidos de Alto Rendimiento/métodos , Mutación , Análisis de Secuencia de ADN/métodos , Fosfatasa Alcalina/genética , Enfermedades del Sistema Endocrino/etiología , Enfermedades del Sistema Endocrino/prevención & control , Enfermedades del Sistema Endocrino/terapia , Endocrinología/métodos , Pruebas Genéticas , Humanos , Hipofosfatasia/genética , Hipofosfatasia/patología , Hipofosfatasia/terapiaRESUMEN
New insights from a rapidly developing field of research have ushered in a new era of understanding of the complexity of host-microbe interactions within the human body. The paradigm shift from culturing to metagenomics has provided an insight into the complex diversity of the microbial species that we harbor, revealing the fact that we are in fact more microbes than human cells. The largest consortium of these microbes resides in the gut and is called the gut microbiota. This new science has expanded the ability to document shifts in microbial populations to an unparalleled degree. It is now understood that signals from the microbiota provide trophic, nutritional, metabolic, and protective effects for the development and maintenance of the host digestive, immune, and neuroendocrine system. Evidence linking changes in the gut microbiota to gastrointestinal and extraintestinal disorders like irritable bowel syndrome, inflammatory bowel disease, obesity, diabetes, and celiac disease have begun to emerge recently. Probiotics act through diverse mechanisms positively affecting the composition and/or function of the commensal microbiota and alter host immunological responses. Well-controlled intervention trials, systematic reviews, and meta-analysis provide convincing evidence for the benefit of probiotics in prevention and treatment of gastrointestinal as well as extraintestinal disorders.